A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer. Article

Full Text via DOI: 10.1200/JCO.2021.39.15_suppl.TPS3156 Web of Science: 000708120306235

International Collaboration

Cited authors

Bessudo A, Cohen EEW, Gutierrez R, Johnson DH, Rosenberg A, Sukari A, Stemmer SM, Weinberg BA, Reuveni H, Schickler M, Liang BC

Authors

Johnson, Daniel, MD

Publication date

2021

Published in

Journal of Clinical Oncology Journal

International Standard Serial Number (ISSN)

0732-183X

Number of pages

3

Volume

39

Issue

15